Natixis’s Axsome Therapeutics AXSM Stock Holding History

Natixis’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$50.9K	Buy	+301	New	+$52K	﹤0.01%	982
2025 Q4	–	Sell	-485	Closed	-$58.9K	–	1129
2025 Q3	$58.9K	Hold	485	–	–	﹤0.01%	927
2025 Q2	$50.6K	Buy	+485	New	+$51.4K	﹤0.01%	880
2025 Q1	–	Sell	-748	Closed	-$63.3K	–	985
2024 Q4	$63.3K	Sell	748 -142	-16%	-$13.1K	﹤0.01%	870
2024 Q3	$80K	Sell	890 -32,762	-97%	-$2.86M	﹤0.01%	762
2024 Q2	$2.71M	Buy	33,652 +32,417	+2,625%	+$2.4M	0.02%	368
2024 Q1	$98.6K	Buy	1,235 +148	+14%	+$12.4K	﹤0.01%	777
2023 Q4	$86.5K	Sell	1,087 -57	-5%	-$3.81K	﹤0.01%	787
2023 Q3	$80K	Buy	+1,144	New	+$85.5K	﹤0.01%	799

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Natixis's AXSM Position: Q1 2026 in Review

Natixis opened a new position in Axsome Therapeutics (AXSM) in Q1 2026: 301 shares worth $50.9K. The stake represents ﹤0.01% of the portfolio and ranks #982 among its holdings. This is a return to the name: Natixis previously reported a position in AXSM as recently as Q3 2025.

Natixis first reported a position in AXSM in Q3 2023 and has held it in 9 quarters since. The position peaked at $2.71M in Q2 2024. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Natixis held 301 shares of Axsome Therapeutics worth $50.9K as of Q1 2026.
Axsome Therapeutics was a new Natixis position in Q1 2026.
Axsome Therapeutics made up ﹤0.01% of Natixis's portfolio in Q1 2026, its #982 holding.
Natixis first reported a position in Axsome Therapeutics in Q3 2023 and has held it in 9 quarters since.
Natixis's Axsome Therapeutics position peaked at $2.71M in Q2 2024.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.